Minutes
Chairman
Date
Page
John Waterton / Chris Taylor
30 September 2002
1/ 4
Participants
Copies to
Jo Naish
Chris Taylor
Leif Hultin
John Waterton
Alan Jackson
Emily Xanthopoulos
Geoff Parker
Shane Maloney
Andrew Holmes
Jean Tessier
Simon Young
Judith Adams
Steve Williams
Anders Andersson
Jonathon Bowyer
Steve Wedge
Andy Turnbull
Hakan Wennbo
Rose Maciewicz
Alan Cross
Charles Hutchinson
Meeting date
Location
30 August 2002
University of Manchester (t/c Mölndal)
Subject
Reference
AstraZeneca Manchester Strategic Alliance
Sixth meeting
Status of the collaboration arrangements
Agreement – Action Jo and Emily to add the signed version to the website
Press release – Action John to discuss with Shane
Website - thanks to Jo and Emily for keeping this really excellent website on up to
date. The url is http://www.isbe.man.ac.uk/az , the username is AZStrategic, and
the password is T23Dffe
Project Reports
Project reports (all available on the website) were presented for the following
projects:
 Reference 1/21 - Volumetric MRI in the articular cartilage of the hip
http://www.isbe.man.ac.uk/az/docs/reports/p21progress.ppt. Project 1 is complete.
Project 21 awaits the development of segmentation routines using orthogonal
planes in EndPoint. Action EX/JN to pursue with iMorphics
 Reference 2/17 - Hydration analysis from gradient echo MRI
http://www.isbe.man.ac.uk/az/docs/reports/p17progress.pdf . Project 2 is complete.
Several technical difficulties were noted: partial volume averaging, motion, receiver
inhomogeneity and fat suppression affecting the phantom. Project 17 provided
intrguing histograms from the OA16 study. Action JCW/JN to pursue these findings
AstraZeneca
Mereside
Alderley Park
Macclesfield
Cheshire
SK10 4TG
Tel: +44 (0) 1625 582828
Fax: +44 (0) 1625 583074
www.astrazeneca.com
AstraZeneca UK Limited
Registered in England No:3674842
Registered Office:
15 Stanhope Gate
London W1K 1LN
England
Chairman
Date
Page
John Waterton / Chris Taylor
30 September 2002
2/4
 Reference 3/22 - Rheumatoid Arthritis in the hand (Reference 22 is the 2D SSM
pilot). This project has ceased due to lack of technical feasibility (missing fingers).
http://www.isbe.man.ac.uk/az/docs/reports/p22progress.ppt Action: JCW/EX/CH/JA
to consider opions for further work after the CP79 investigator meeting on 16/9/2.
EX to provide abstract for IPEM to AZ
 Reference 4 - CSF flow in the cerebral aqueduct. This project has been
completed. Results were presented at MIUA. Alan Jackson is drafting a paper on
the vascular compliance problem in this group of patients.
 Reference 5 – lung. Data have been acuired from 4 patients recruited to the
CP73 trial
 Reference 9 – SPENT. Unlikely to beuseful in AD but maybe in OA. Possibly
discuss with R Ordidge? Technical note – Magn. Reson. Imaging?
http://www.isbe.man.ac.uk/az/docs/reports/p9progress.pdf
Project proposals
Four project proposals were discussed. After discussion, proposals 24 and 25 were
merged into a protocol development project for 3T. The outcome was as stated in
the table below.
Action: JN/EX to liase with ISBE colleagues plus Drs Embleton/Woodcock to
prepare schedules to append to agreement. JCW to liase with AZ colleagues (Drs
Young, Higenbotham, Cross, Andersson) in respect of proposals 23/27 LH to liase
with AZ colleagues in respect of proposal 26
It was noted in the light of previous concerns, excellent proposals had now been
brought forward in a wide range of AZ therapy areas.
Date of next meeting (video and/or net-meeting)
January 2003
Minutes
Disease
area
Proposal
AZ business value
Technical
feasibility
Academic
interest
Dependencies
Decisions
COPD
23 Development and Assessment of
Quantitative Oxygen-Enhanced MRI in
Patients with Obstructive Lung Disease
Medium-High
Medium-High
Medium
none
Approved
AD
24 Measuring Disease Progression In
Alzheimer’s Disease
Medium
Medium-High
Medium
IRC?
Medium-Low
Medium
Medium-High
Medium-High
Medium
Medium-High
IBD
25 Quantification of CSF and Cerebral
Blood Flow in Alzheimers Disease
26 Contrast enhanced MRI in
inflammatory bowel disease
AD
27 AD protocol development (24/25
merged)
AD
AstraZeneca
Mereside
Alderley Park
Macclesfield
Cheshire
SK10 4TG
Tel: +44 (0) 1625 582828
Fax: +44 (0) 1625 583074
www.astrazeneca.com
Dr Embleton?
Merge and
work up 3T
proposal
Approved
Approved
AstraZeneca UK Limited
Registered in England No:3674842
Registered Office:
15 Stanhope Gate
London W1K 1LN
England
Chairman
Date
Page
John Waterton / Chris Taylor
30 September 2002
4/4